A. Tang

发表

Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.

C. Presant, J. Waisman, J. S. Lee, 2021, Journal of geriatric oncology.

Aberrant expression of E-cadherin in lung tissues of patients with probable lung cancer.

Yong Duan, Hua Liu, A. Tang, 2012, Asian Pacific journal of cancer prevention : APJCP.

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

J. Waisman, J. S. Lee, P. Frankel, 2022, Cancers.

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.

C. Presant, J. S. Lee, P. Frankel, 2021, European journal of cancer.

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple Negative Breast Cancer.

J. Waisman, J. S. Lee, P. Frankel, 2020, The oncologist.

A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.

S. Highlander, J. Waisman, J. S. Lee, 2020, The oncologist.

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.

J. Waisman, P. Frankel, J. Mortimer, 2021 .

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

H. Yin, J. S. Lee, S. Blanchard, 2019, Breast Cancer Research.

A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.

J. Waisman, P. Frankel, G. Somlo, 2019, Journal of Clinical Oncology.

Phase I study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer.

J. Waisman, S. Chaurasiya, J. Mortimer, 2022, Journal of Clinical Oncology.

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer

J. Waisman, P. Frankel, G. Somlo, 2022, Cancer.

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

H. Yin, J. S. Lee, S. Blanchard, 2019, Breast Cancer Research.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

J. Waisman, J. S. Lee, P. Frankel, 2023, Cancer Immunology, Immunotherapy.

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

J. Waisman, P. Frankel, L. Vora, 2023, The oncologist.